Evommune, Inc. (EVMN) Earnings History
Net Loss3 years of earnings data (2023–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Evommune, Inc. (EVMN) Earnings Overview
As of July 8, 2026, Evommune, Inc. (EVMN) reported trailing twelve-month net income of -$76M, reflecting +4.0% year-over-year growth. The company earned $-2.26 per diluted share over the past four quarters, with a net profit margin of -529.8%.
Looking at the long-term picture, EVMN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$34M in fiscal 2023.
Evommune, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), ARDX (-$58M net income, -15.1% margin), CLDX (-$284M net income, -17253.3% margin), EVMN has comparable earnings metrics. Compare EVMN vs IMVT →
EVMN Earnings vs Peers
Earnings metrics vs comparable public companies
EVMN Historical Earnings Data (2023–2025)
3 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$69M | -3.1% | -$81M | $-2.18 | -529.8% | -623.6% |
| 2024 | -$67M | -96.2% | -$70M | $-2.27 | -954.4% | -1000.2% |
| 2023 | -$34M | - | -$38M | $-1.13 | -681.1% | -757.0% |
Download Data
Export EVMN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EVMN — Frequently Asked Questions
Quick answers to the most common questions about buying EVMN stock.
What is EVMN earnings per share (EPS)?
EVMN trailing twelve-month (TTM) diluted EPS is $-2.26, reflecting +4.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2023 to 2025 is available in the table on this page.
What is Evommune, Inc.'s net income?
Evommune, Inc. (EVMN) trailing twelve-month net income is $-76M as of 2025. Earnings grew +4.0% year-over-year.
Is EVMN profitable?
EVMN is not currently profitable on a TTM basis, reporting a net loss of $-76M. Net margin is -529.8%. Investors should monitor for a return to profitability.
What is EVMN's earnings growth rate?
EVMN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2023 to 2025.
What are EVMN's profit margins?
Evommune, Inc. net profit margin is -529.8%, operating margin is -623.6%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -224.6%.
Is EVMN growing earnings?
EVMN earnings growth is slowing. Current YoY EPS growth of +4.0% trails the 5-year CAGR of N/A. TTM net income is $-76M.
What was EVMN's best earnings year?
Evommune, Inc.'s highest annual net income on record is $-34M, achieved in fiscal year 2023. Earnings history on this page spans 2023 to 2025 and includes all annual and quarterly figures.
What were EVMN's earnings last quarter?
EVMN's most recent reported quarter was Q1 2026. Net income was $-22M with diluted EPS of $-0.64. For a full breakdown of all quarters, see the quarterly earnings table on this page.